128 related articles for article (PubMed ID: 38387803)
21. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
22. Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.
Gugel I; Zipfel J; Hartjen P; Kluwe L; Tatagiba M; Mautner VF; Schuhmann MU
Childs Nerv Syst; 2020 Oct; 36(10):2471-2480. PubMed ID: 32548671
[TBL] [Abstract][Full Text] [Related]
23. Updates on Tumor Biology in Vestibular Schwannoma.
Nourbakhsh A; Dinh CT
Otolaryngol Clin North Am; 2023 Jun; 56(3):421-434. PubMed ID: 37121611
[TBL] [Abstract][Full Text] [Related]
24. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Zhao Y; Liu P; Zhang N; Chen J; Landegger LD; Wu L; Zhao F; Zhao Y; Zhang Y; Zhang J; Fujita T; Stemmer-Rachamimov A; Ferraro GB; Liu H; Muzikansky A; Plotkin SR; Stankovic KM; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E2077-E2084. PubMed ID: 29440379
[TBL] [Abstract][Full Text] [Related]
25. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
[TBL] [Abstract][Full Text] [Related]
26. Current Management of Large Vestibular Schwannomas for NF2 Patients in a National Reference Center.
Comes PC; Peyre M; Sanson M; Sterkers O; Bernardeschi D; Kalamarides M
Laryngoscope; 2021 Jan; 131(1):E98-E107. PubMed ID: 33270257
[TBL] [Abstract][Full Text] [Related]
27. ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.
Ahmad ZK; Brown CM; Cueva RA; Ryan AF; Doherty JK
Otol Neurotol; 2011 Jul; 32(5):841-7. PubMed ID: 21659924
[TBL] [Abstract][Full Text] [Related]
28. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
[TBL] [Abstract][Full Text] [Related]
29. The comparable tumour microenvironment in sporadic and
Gregory GE; Jones AP; Haley MJ; Hoyle C; Zeef LAH; Lin IH; Coope DJ; King AT; Evans DG; Paszek P; Couper KN; Brough D; Pathmanaban ON
Brain Commun; 2023; 5(4):fcad197. PubMed ID: 37680691
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
Lu VM; Ravindran K; Graffeo CS; Perry A; Van Gompel JJ; Daniels DJ; Link MJ
J Neurooncol; 2019 Sep; 144(2):239-248. PubMed ID: 31254266
[TBL] [Abstract][Full Text] [Related]
31. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.
Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF
Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957
[TBL] [Abstract][Full Text] [Related]
32. Primary culture of human vestibular schwannomas.
Schularick NM; Clark JJ; Hansen MR
J Vis Exp; 2014 Jul; (89):. PubMed ID: 25079666
[TBL] [Abstract][Full Text] [Related]
33. Human vestibular schwannoma growth in the nude mouse: evaluation of a modified subcutaneous implantation model.
Stidham KR; Roberson JB
Am J Otol; 1997 Sep; 18(5):622-6. PubMed ID: 9303159
[TBL] [Abstract][Full Text] [Related]
34. Genetic landscape of sporadic vestibular schwannoma.
Håvik AL; Bruland O; Myrseth E; Miletic H; Aarhus M; Knappskog PM; Lund-Johansen M
J Neurosurg; 2018 Mar; 128(3):911-922. PubMed ID: 28409725
[TBL] [Abstract][Full Text] [Related]
35. Establishment of vestibular schwannoma primary cell cultures obtained from cavitron ultrasonic surgical aspirator tissue material.
Leisz S; Klause CH; Becker AL; Scheer M; Simmermacher S; Strauss C; Scheller C
J Neurosci Methods; 2023 Sep; 397():109955. PubMed ID: 37611876
[TBL] [Abstract][Full Text] [Related]
36. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
[TBL] [Abstract][Full Text] [Related]
37. Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma.
Karajannis MA; Hagiwara M; Schreyer M; Haque S
Neuro Oncol; 2019 Jun; 21(6):822-824. PubMed ID: 31180122
[No Abstract] [Full Text] [Related]
38. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
39. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Imaging in the Diagnosis and Management of Patients With Vestibular Schwannomas.
Dunn IF; Bi WL; Mukundan S; Delman BN; Parish J; Atkins T; Asher AL; Olson JJ
Neurosurgery; 2018 Feb; 82(2):E32-E34. PubMed ID: 29309686
[TBL] [Abstract][Full Text] [Related]
40. Molecular biology of vestibular schwannomas.
Chang LS; Welling DB
Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
